A December 2015 workshop in Lausanne reviewed the policy and stakeholder actions needed to accelerate biomedical research and health innovation for Alzheimer’s disease and other dementias. There is consensus across all stakeholders to move from global agenda setting in Alzheimer’s disease to action oriented programmes and implementation.
Accelerating innovation for Alzheimer’s disease and other dementias is a key challenge. An OECD workshop in November 2014 provided an international forum for all stakeholders to drive forward a change in the global paradigm in biomedical research and health innovation for Alzheimer’s disease and other dementias.
This report looks at the roles and options of stakeholders (governments, regulatory agencies, academia, small and mid-size biotech companies, the pharmaceutical industry, and patient organisations) in public-private partnerships for product development in Alzheimer’s disease and other dementias.
This report explores the characteristics of nanotechnology as it relates to technology convergence i.e. actual instances of the convergence of different technology streams in the research and innovation environments within laboratories and companies. It examines four application areas in which nanotechnology plays a strong role (green packaging, food safety and security, pharmaceuticals and medical devices).
Several OECD countries have published their plans for the development of a future bioeconomy, in which bio-based materials and production techniques will contribute significantly to economic and environmental sustainability. The case for support for bio-based chemicals and plastics therefore warrants serious attention.
Synthetic biology is an emerging technology that shows promise for investigating some of the burning issues in biological research. It also has the potential to address some of the grand challenges facing society, such as climate change and energy security.
English, PDF, 566kb
This report presents findings from a pilot survey of business activity in nanotechnology and discusses methodological and practical issues (e.g. the use of definitions) for on-going consideration in work on statistics and indicators for nanotechnology. It identifies how work in this area may support the assessment of other emerging technologies via an integrated framework.
This report examines examples of new and emerging governance models that aim to support the responsible development of diagnostics and treatments based on the latest advances in biomedicine. In particular, it presents programmes and initiatives that aim to manage uncertainty in the development and approval of new medical products and thereby to improve the understanding of the risk/benefit balance.
The economic and social impact of chronic brain disorders such as Alzheimer’s disease and other neurodegenerative diseases will become the number one public-health problem worldwide, directly affecting 100 million people by 2050.
This paper explores the development of the bioplastics sector and its role in national bioeconomy strategies. It finds that bioplastics are at a disadvantage compared to some other biobased products, notably biofuels, that often benefit from preferential treatment. It also notes that greater efforts are needed at the international level as regards standards to avoid creating barriers to international trade in biobased products.